<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>New treatments which may change the course of a disease, or which have potential <z:e sem="disease" ids="C0858970" disease_type="Neoplastic Process" abbrv="">carcinogenicity</z:e>, may result in the development of new cytogenetic or clinical disorders </plain></SENT>
<SENT sid="1" pm="."><plain>Three patients with <z:e sem="disease" ids="C0856536" disease_type="Neoplastic Process" abbrv="">Philadelphia chromosome-positive</z:e> (Ph-positive) <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>) who developed new cytogenetic abnormalities after achieving a cytogenetic complete remission (CR) of their Ph-positive disease with interferon alpha (IFN-alpha) based therapy are described </plain></SENT>
<SENT sid="2" pm="."><plain>Patient 1 developed chromosomal abnormalities involving chromosomes 5 (5q13-34) and later 7 (<z:mp ids='MP_0004026'>monosomy</z:mp> 7) 60 months after the start of therapy and 20 months after IFN-alpha was discontinued </plain></SENT>
<SENT sid="3" pm="."><plain>A <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> was noted 83 months from the start of therapy </plain></SENT>
<SENT sid="4" pm="."><plain>Patient 2 developed a myeloproliferative syndrome with 18p11 chromosomal abnormalities 90 months after the start of the therapy and 60 months after IFN-alpha was discontinued </plain></SENT>
<SENT sid="5" pm="."><plain>Patient 3 developed a chromosome 11 abnormality (11q21-23) 23 months after the start of therapy, without hematological manifestations </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> three patients remain in cytogenetic CR of Ph-positive disease with the hypermetaphase fluorescent in situ hybridization and polymerase chain reaction studies for BCR/ABL showing <z:e sem="disease" ids="C0242596" disease_type="Neoplastic Process" abbrv="MRD">minimal residual disease</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>The emergence of new cytogenetic or clinical disorders in patients with <z:mp ids='MP_0005481'>CML</z:mp> on IFN-alpha therapy needs to be monitored </plain></SENT>
<SENT sid="8" pm="."><plain>These findings may be related to changing the natural course of <z:mp ids='MP_0005481'>CML</z:mp>, to therapy, or to the emergence of suppressed clones in a stem cell disorder </plain></SENT>
</text></document>